Factory Provide Anti-Cancer Raw Powder CAS 183133-96-2 Cabazitaxel

Introduction

Product Name :  Cabazitaxel

Othe name :;Cabazitaxel;XRP6258;RPR-116258A;TAXOID XRP6258;TXD 258;

CAS No. 183133-96-2

Molecular Formula: C45H57NO14

MW: 835.93

Assay: 99%
Appearance: White powder

Melting Point :180 °C

Boiling Point :870.7±65.0 °C(Predicted)

Density :1.31

Storage :Sealed in dry,Room Temperature

Cabazitaxel (previously XRP-6258) is a semi-synthetic derivative of a natural taxoid. It was developed by Sanofi-Aventis and was approved by the U.S. FDA for the treatment of hormone-refractory prostate cancer on June 17, 2010. It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy.

Cabazitaxel in combination is a treatment option for hormone-refractory prostate cancer following docetaxel-based treatment.

Cabazitaxel anticancer mechanism and characteristics similar with docetaxel, belongs to anti-microtubule drugs. Cabazitaxel through binding to tubulin, promoting their assembly into microtubules, and can prevent these have assembled a microtubule disintegration of the stabilization of microtubules, thereby inhibiting cell mitosis, and interphase cellular functions (interphasecellularfunctions) of play.

Specification 

Application

1. Cabazitaxel's mechanism and characteristics are similar to docetaxel and belong to anti-microtubule.
2. Cabazitaxel promotes its assembly into microtubules by binding to tubulin, while preventing the disassembly of these assembled microtubules, stabilizing microtubules, thereby inhibiting cell mitosis, and interphase cellular functions.